Clofazimine, but Not Isoniazid or Rifampicin, Augments Platelet Activation in vitro

Although the inclusion of the cationic amphiphilic, anti-mycobacterial agent, clofazimine, in the chemotherapeutic regimens of patients with multidrug-resistant tuberculosis (TB) has contributed to improved outcomes, concerns remain about the cardiotoxic potential of this agent. Accordingly, the cur...

Descripción completa

Detalles Bibliográficos
Autores principales: Anderson, Ronald, Theron, Annette J., Nel, Jan G., Durandt, Chrisna, Cholo, Moloko C., Feldman, Charles, Tintinger, Gregory R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255828/
https://www.ncbi.nlm.nih.gov/pubmed/30515097
http://dx.doi.org/10.3389/fphar.2018.01335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255828/
https://www.ncbi.nlm.nih.gov/pubmed/30515097
http://dx.doi.org/10.3389/fphar.2018.01335

Ejemplares similares